Edition:
United States

H Lundbeck A/S (LUN.CO)

LUN.CO on Copenhagen Stock Exchange

302.70DKK
11 Dec 2017
Change (% chg)

kr.-1.20 (-0.39%)
Prev Close
kr.303.90
Open
kr.305.00
Day's High
kr.306.00
Day's Low
kr.300.70
Volume
303,338
Avg. Vol
417,969
52-wk High
kr.413.20
52-wk Low
kr.266.40

Chart for

About

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimer’s disease, Bipolar disorder, depression, epilepsy, Huntington’s disease, Parkinson’s disease and... (more)

Overall

Beta: 0.95
Market Cap(Mil.): kr.60,490.63
Shares Outstanding(Mil.): 199.05
Dividend: 2.45
Yield (%): 0.81

Financials

  Industry Sector
P/E (TTM): -- 32.13 15.67
EPS (TTM): -- -- --
ROI: -- 15.10 34.62
ROE: -- 16.59 16.00

BRIEF-Lundbeck: Brintellix Approved In China

* LAUNCH IS EXPECTED TO COMMENCE IN Q2 2018. Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Dec 04 2017

BRIEF-Acorda announces royalty monetization transactions for $53 mln

* Acorda announces royalty monetization transactions for $53 million

Nov 17 2017

UPDATE 2-Financials weigh on European stocks as "Trumpflation" hopes fade

* MSCI EMU earnings growth tracking 7 percent (Adds closing prices, comments)

Nov 08 2017

Shares in Denmark's Lundbeck drop as sales of key drugs disappoint

COPENHAGEN, Nov 8 Shares in Danish pharmaceutical firm Lundbeck fell as much as 6.8 percent on Tuesday as third-quarter sales of its newer drugs, such as those to treat bipolar disorder and depression, undershot market expectations.

Nov 08 2017

BRIEF-Lundbeck CEO sees U.S. prices to increase steadily

* INTERIM CEO SAYS EXPECTS U.S. PRICE INCREASES TO CONTINUE AT CURRENT LEVELS GOING FORWARD Further company coverage: (Reporting by Julie Astrid Thomsen)

Nov 08 2017

BRIEF-Lundbeck Q3 EBIT above expectations at DKK 1.42‍​ bln

* LUNDBECK INCREASED OPERATING PROFIT (EBIT) WITH 126% AND EPS BY 182% IN THE FIRST NINE MONTHS OF 2017

Nov 08 2017

BRIEF-Otsuka Canada Pharmaceutical says Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​

* Otsuka Canada Pharmaceutical Inc-Health Canada approves Otsuka and Lundbeck's Abilify Maintena as treatment for bipolar I disorder in adults​ Source text for Eikon: Further company coverage:

Nov 02 2017

BRIEF-Otsuka Holdings unit and Lundbeck to initiate third Phase 3 trial to evaluate brexpiprazole in treatment of agitation in patients with dementia of Alzheimer's type

* Says co's unit Otsuka Pharmaceutical Co., Ltd. and H. Lundbeck A/S will initiate a third clinical phase 3 study for brexpiprazole in the treatment of agitation in patients with dementia of the Alzheimer's type, in the first half of 2018

Nov 01 2017

BRIEF-Lundbeck and Otsuka will start third clinical phase III study

* ‍H. LUNDBECK A/S AND OTSUKA ANNOUNCE WILL INITIATE A THIRD CLINICAL PHASE III STUDY FOR BREXPIPRAZOLE​

Nov 01 2017

BRIEF-Lundbeck says Anders Gotzsche to be interim CEO from Nov 1

* ‍BOARD DECIDED THAT AS OF NOV 1 ANDERS GÖTZSCHE WILL TAKE OVER OPERATIONAL MANAGEMENT OF CO AS INTERIM CEO UNTIL NEW CEO IS IN PLACE​ Source text for Eikon: Further company coverage:

Oct 30 2017

Earnings vs. Estimates